However, when mice were first treated with EVs before anti–PD-1/anti–PD-L1 treatment in the therapeutic model, no delay in tumor growth or improvement in mouse survival was observed (Supplementary Fig. S8A-S8C). Here, PDCD1 is linked to neoplasm.